Loading
A phase 1/2 trial of Raludotatug deruxtecan, Carboplatin, Paclitaxel / nab-paclitaxel in ovarian cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) is a phase 1/2 interventional study registered as NCT06843447 by Merck Sharp & Dohme LLC, with 605 participants planned, started 2025-04-15 and due to reach its primary completion in 2029-03-27. Interventions recorded: Raludotatug Deruxtecan, Carboplatin, Paclitaxel, Bevacizumab, Rescue Medication. Conditions listed: Ovarian Cancer Recurrent. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares High-grade serous ovarian cancer, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
Shares Raludotatug deruxtecan, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Raludotatug deruxtecan, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Raludotatug deruxtecan, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Raludotatug deruxtecan, Merck & Co. (MSD).
Shares High-grade serous ovarian cancer, Antibody-drug conjugate (ADC), Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/